Literature DB >> 22493236

Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Geneviève Oligny-Longpré1, Maithé Corbani, Joris Zhou, Mireille Hogue, Gilles Guillon, Michel Bouvier.   

Abstract

G protein-coupled receptors (GPCRs) have been shown to activate the mitogen-activated protein kinases, ERK1/2, through both G protein-dependent and -independent mechanisms. Here, we describe a G protein-independent mechanism that unravels an unanticipated role for β-arrestins. Stimulation of the V2 vasopressin receptor (V2R) in cultured cells or in vivo in rat kidney medullar collecting ducts led to the activation of ERK1/2 through the metalloproteinase-mediated shedding of a factor activating the insulin-like growth factor receptor (IGFR). This process was found to be both Src- and β-arrestin-dependent. Whereas Src was found to act upstream of the metalloproteinase activation and be required for the release of the IGFR-activating factor, β-arrestins were found to act downstream of the IGFR transactivation. Unexpectedly, the engagement of β-arrestins by the IGFR but not by the V2R was needed to promote the vasopressin-stimulated ERK1/2 activation, indicating that a pool of β-arrestins distinct from those β-arrestins recruited to the V2R acts downstream of the receptor tyrosine kinase to activate ERK1/2. Such a dual site of action for β-arrestins helps explain the pleiotropic actions of this scaffolding protein. Given the role that V2R-stimulated ERK1/2 plays in kidney cell proliferation, this transactivation mechanism may have important implications for renal pathophysiology. Still, the role of β-arrestins downstream of a transactivation event is not limited to the V2R, because we observed a similar involvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it may be a general mechanism shared among GPCRs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493236      PMCID: PMC3340024          DOI: 10.1073/pnas.1112422109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  79 in total

1.  Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src.

Authors:  A Suzuki; N Kadota; T Hara; Y Nakagami; T Izumi; T Takenawa; H Sabe; T Endo
Journal:  Oncogene       Date:  2000-11-30       Impact factor: 9.867

2.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex.

Authors:  K A DeFea; Z D Vaughn; E M O'Bryan; D Nishijima; O Déry; N W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 3.  Development of matrix metalloproteinase inhibitors in cancer therapy.

Authors:  M Hidalgo; S G Eckhardt
Journal:  J Natl Cancer Inst       Date:  2001-02-07       Impact factor: 13.506

4.  Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro.

Authors:  D Byun; S Mohan; M Yoo; C Sexton; D J Baylink; X Qin
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

5.  Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular Ca2+, PYK-2, and p60(src).

Authors:  S J Keely; S O Calandrella; K E Barrett
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

6.  PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.

Authors:  X Li; A Pontén; K Aase; L Karlsson; A Abramsson; M Uutela; G Bäckström; M Hellström; H Boström; H Li; P Soriano; C Betsholtz; C H Heldin; K Alitalo; A Ostman; U Eriksson
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

7.  Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds.

Authors:  L M Luttrell; F L Roudabush; E W Choy; W E Miller; M E Field; K L Pierce; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

8.  Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Authors:  John S P Yuen; Erdem Akkaya; Yong Wang; Megumi Takiguchi; Sandra Peak; Mark Sullivan; Andrew S Protheroe; Valentine M Macaulay
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

9.  Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus.

Authors:  L S Barak; R H Oakley; S A Laporte; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

Review 10.  Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.

Authors:  J S Biscardi; R C Ishizawar; C M Silva; S J Parsons
Journal:  Breast Cancer Res       Date:  2000-03-07       Impact factor: 6.466

View more
  13 in total

Review 1.  Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors.

Authors:  Rebecca Chaplin; Lyna Thach; Morley D Hollenberg; Yingnan Cao; Peter J Little; Danielle Kamato
Journal:  J Cell Commun Signal       Date:  2017-02-06       Impact factor: 5.782

Review 2.  Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Authors:  Markus M Rinschen; Bernhard Schermer; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

3.  Receptor sequestration in response to β-arrestin-2 phosphorylation by ERK1/2 governs steady-state levels of GPCR cell-surface expression.

Authors:  Justine S Paradis; Stevenson Ly; Élodie Blondel-Tepaz; Jacob A Galan; Alexandre Beautrait; Mark G H Scott; Hervé Enslen; Stefano Marullo; Philippe P Roux; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

4.  Role for engagement of β-arrestin2 by the transactivated EGFR in agonist-specific regulation of δ receptor activation of ERK1/2.

Authors:  Le-Sha Zhang; Yu-Jun Wang; Yun-Yue Ju; Gui-Ying Zan; Chi Xu; Min-Hua Hong; Yu-Hua Wang; Zhi-Qiang Chi; Jing-Gen Liu
Journal:  Br J Pharmacol       Date:  2015-09-23       Impact factor: 8.739

5.  Key phosphorylation sites in GPCRs orchestrate the contribution of β-Arrestin 1 in ERK1/2 activation.

Authors:  Mithu Baidya; Punita Kumari; Hemlata Dwivedi-Agnihotri; Shubhi Pandey; Madhu Chaturvedi; Tomasz Maciej Stepniewski; Kouki Kawakami; Yubo Cao; Stéphane A Laporte; Jana Selent; Asuka Inoue; Arun K Shukla
Journal:  EMBO Rep       Date:  2020-07-26       Impact factor: 9.071

Review 6.  Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors.

Authors:  Sabrina M de Munnik; Martine J Smit; Rob Leurs; Henry F Vischer
Journal:  Front Pharmacol       Date:  2015-03-09       Impact factor: 5.810

Review 7.  Cell-surface receptors transactivation mediated by g protein-coupled receptors.

Authors:  Fabio Cattaneo; Germano Guerra; Melania Parisi; Marta De Marinis; Domenico Tafuri; Mariapia Cinelli; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2014-10-29       Impact factor: 5.923

Review 8.  Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.

Authors:  Leonard Girnita; Claire Worrall; Shin-Ichiro Takahashi; Stefan Seregard; Ada Girnita
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

Review 9.  Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research.

Authors:  Zhixiang Wang
Journal:  Int J Mol Sci       Date:  2016-01-12       Impact factor: 5.923

10.  Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling.

Authors:  Jialu Wang; Kenji Hanada; Dean P Staus; Michael A Makara; Giri Raj Dahal; Qiang Chen; Andrea Ahles; Stefan Engelhardt; Howard A Rockman
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.